Citius Oncology (CTOR) Equity Ratio (2021 - 2026)

Citius Oncology's Equity Ratio history runs 6 years deep, the most recent figure standing at 0.35 for Q1 2026.

• In Q1 2026, Equity Ratio fell 10.15% year-over-year to 0.35; the TTM figure through Mar 2026 stood at 0.35 (down 10.15% YoY), while the FY2025 annual figure was 0.44, down 18.73% from the prior year.
• Equity Ratio was 0.35 for Q1 2026 at Citius Oncology, down from 0.53 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 141.26 in Q3 2022 to a low of 0.0 in Q2 2023.
• Historically, Equity Ratio has averaged 9.73 across 5 years, with a median of 0.39 in 2025.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio slumped 99.62% in 2023, then soared 1228873.15% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.01 in 2022, then jumped by 6075.84% to 0.31 in 2023, then surged by 45.83% to 0.46 in 2024, then advanced by 16.4% to 0.53 in 2025, then sank by 34.06% to 0.35 in 2026.
• The last three Equity Ratio figures came in at 0.35 (Q1 2026), 0.53 (Q4 2025), and 0.44 (Q3 2025), per Business Quant data.